Zealand Pharma 2Q25 results confirm timelines, upcoming CMD in December 2025
Zealand's 2Q25 results hold no surprises, and show that the company is on track operationally with pipeline timelines being reiterated. While no big data readouts are expected for the remainder of the year, the company is gearing up for a news heavy 1H26 and we most look forward to phase 2b results with petrelintide (amylin analog, partnered with Roche). Zealand reported a cash position of DKK 16,578m, and expects an additional $ 250m in anniversary payments under the Roche agreement in addition to potential milestones of $ 1.2b mostly linked to phase 3 petrelintide initiation. We reiterate ou...